Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $448.40 Wednesday, on what proved to be an all-around rough trading ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. What Are Smart ...

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhD <li /> Dottie Caplan promoted to Executive Vi ...

RBC Capital slightly trimmed Vertex Pharmaceuticals’ price target from $423 to $420, but the firm’s rating stayed the course.

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

Potentially more than $850 million from the settlement would go directly to individual victims, making it different from the ...

The ROBO Global Healthcare Technology & Innovation Index offers unique, targeted exposure to innovators. Click to read.